Scientific Resources

News

04/24/2024

Ciliatech’s glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease

First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma.

News

12/05/2023

Ciliatech releases new design of glaucoma surgical device CID, following patent reinforcement

Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform.

News

10/23/2023

We are recruiting a ISO 13485 Quality Assurance / Regulatory Affairs Manager

You will be responsible for managing and adapting the quality system to meet the various standards required for international commercialization (ISO 13485, MDR 2017/745, MDSAP, FDA 21 CFR 820...), as well as preparing the necessary documentation for registrations outside Europe...

Technical Articles

10/23/2023

Alleviating the burden of PACG treatment

Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. Moreover, the currently available treatment options for the management PACG remain relatively limited. The cilioscleral inter-positioning device is a novel minimally invasive implant designed to increase uveoscleral outflow without entering the chamber. This unique approach to lower IOP represents a new, efficient, and safe surgical option to reduce intraocular pressure for patients with PACG.

News

09/07/2023

Preliminary one-year study results on treating open and narrow angle glaucoma with CID

Ciliatech presents preliminary one-year study results on treating open and narrow angle glaucoma with CID at Ophthalmology Futures Symposium.

News

08/09/2023

Ophthalmology Times Europe

At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).

Technical Articles

07/19/2023

How the cilioscleral approach fits in with other glaucoma surgical techniques

Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,

News

06/28/2023

Two-year post-operative results on new cilio-scleral surgical approach for treating glaucoma

Results from second CID (Cilio-scleral Interposition Device) study confirm sustained decrease in intraocular pressure (IOP), while preserving anterior chamber of eye

News

05/17/2023

Ciliatech is recruiting a Clinical Affairs Manager

You will be the 2nd employee of the Company, reporting directly to the CEO, and in close connection withe the medical Director...

News

04/25/2023

Scientific Resources

Ciliatech’s glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease

First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma.

Ciliatech releases new design of glaucoma surgical device CID, following patent reinforcement

Second-generation CID (Cilioscleral Interpositioning Device) makes cilioscleral surgical procedure, which leaves anterior chamber of eye untouched, less invasive and easier to perform.

We are recruiting a ISO 13485 Quality Assurance / Regulatory Affairs Manager

You will be responsible for managing and adapting the quality system to meet the various standards required for international commercialization (ISO 13485, MDR 2017/745, MDSAP, FDA 21 CFR 820...), as well as preparing the necessary documentation for registrations outside Europe...

Alleviating the burden of PACG treatment

Preliminary one-year study results on treating open and narrow angle glaucoma with CID

Ciliatech presents preliminary one-year study results on treating open and narrow angle glaucoma with CID at Ophthalmology Futures Symposium.

Ophthalmology Times Europe

At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).

How the cilioscleral approach fits in with other glaucoma surgical techniques

Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,

Two-year post-operative results on new cilio-scleral surgical approach for treating glaucoma

Results from second CID (Cilio-scleral Interposition Device) study confirm sustained decrease in intraocular pressure (IOP), while preserving anterior chamber of eye

Ciliatech is recruiting a Clinical Affairs Manager

You will be the 2nd employee of the Company, reporting directly to the CEO, and in close connection withe the medical Director...

Ciliatech raises €3.5M in Series A funding

Funds will advance development of Ciliatech’s disruptive glaucoma implant CID and initiate clinical trials in Europe, paving way for CE mark approval